Comparison of Effectiveness of Alcohol Septal Ablation Versus Ventricular Septal Myectomy on Acute Care Use for Cardiovascular Disease in Patients With Hypertrophic Cardiomyopathy

2019 ◽  
Vol 124 (8) ◽  
pp. 1272-1278 ◽  
Author(s):  
Yuichi J. Shimada ◽  
Tadahiro Goto ◽  
Hiroo Takayama ◽  
David F.M. Brown ◽  
Shunichi Homma ◽  
...  
Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Sae Morita ◽  
Yanling Zhao ◽  
Kohei Hasegawa ◽  
Muredach P Reilly ◽  
Mathew S Maurer ◽  
...  

Introduction: Septal reduction therapy (SRT) - i.e., septal myectomy and alcohol septal ablation - has been used to treat medically-refractory obstructive hypertrophic cardiomyopathy (HOCM) for a few decades. However, the effects of SRT on the risk of acute cardiovascular (CV) events and all-cause mortality are largely unknown. Hypothesis: SRT is associated with a long-term decrease in acute CV events and a short-term increase in all-cause mortality in patients with HOCM. Methods: We performed a propensity score (PS)-matched study using all-payer databases that capture all hospitalizations and outpatient visits in New York State. We identified patients with HOCM who underwent SRT between January 1, 2007 and December 31, 2014 (i.e., the SRT group) and those who have never had SRT but had at least one hospitalization for HOCM during the same period (i.e., the control group). We performed 1:1 PS matching using age, sex, race/ethnicity, source of payment, season and year of starting event follow-up (i.e., the day of SRT or the index hospitalization), and Elixhauser comorbidity measures. The primary outcomes were (1) acute CV event (i.e., emergency department visit or unplanned hospitalization for CV disease) during 1-360 days and 361-720 days and (2) 7-, 15-, 30-, 180-, and 360-day all-cause mortality. We compared the risk of the outcome event using logistic regression models. Results: The analytic cohort consisted of 690 patients with HOCM (i.e., 345 PS-matched pairs). The SRT group had a lower risk of acute CV event during 361-720 days (OR 0.44; 95% CI, 0.20-0.97; P=0.04) but a higher risk of 7-day mortality (11 vs. 2 in the control group; P=0.03). The SRT group had a non-significant trend towards lower all-cause mortality in longer terms ( Figure ). Conclusion: In this population-based PS-matched study of patients with HOCM, SRT was associated with a reduced risk of acute CV events in the second post-procedure year at the sacrifice of a short-term increase in all-cause mortality.


2020 ◽  
Vol 127 ◽  
pp. 128-134 ◽  
Author(s):  
Alejandro Lemor ◽  
Pedro A. Villablanca ◽  
Seyed Hamed Hosseini Dehkordi ◽  
Ramandeep Mand ◽  
Gabriel A. Hernandez ◽  
...  

2018 ◽  
Vol 66 (4) ◽  
pp. 192-200 ◽  
Author(s):  
Yuting P. Chiang ◽  
Yuichi J. Shimada ◽  
Jonathan Ginns ◽  
Shepard D. Weiner ◽  
Hiroo Takayama

2015 ◽  
Vol 17 (2) ◽  
pp. 46
Author(s):  
A. G. Osiev ◽  
Ye. I. Kretov ◽  
V. P. Kurbatov ◽  
S. P. Mironenko ◽  
R. A. Naydenov ◽  
...  

Hypertrophic cardiomyopathy is a heterogeneous disease characterized by myocardial hypertrophy, without any other systemic or cardiac disorders and with predominant involvement of the interventricular septum. Approximately 25% of patients have a dynamic obstruction of the left ventricular output tract due its constriction and abnormal systolic anterior motion of the mitral valve. Therapeutic strategy for patients with hypertrophic obstructive cardiomyopathy, who remain symptomatic despite drug therapy, includes surgery (septal myectomy) and non-surgical interventions, such as alcohol septal ablation. In the present study the possibility of cardiac MRI with contrast enhancement in the evaluation of the results of endovascular treatment hypertrophic cardiomyopathy and evidence for the benefits of this method in 25 patients with an obstructive form of hypertrophic cardiomyopathy after alcohol septal ablation are discussed.


2019 ◽  
Vol 74 (13) ◽  
pp. B128
Author(s):  
Alejandro Lemor ◽  
Pedro Villablanca ◽  
Gabriel Hernandez ◽  
Tarun Jain ◽  
Ramandeep Mand ◽  
...  

2014 ◽  
Vol 6 (2) ◽  
pp. 199-215 ◽  
Author(s):  
Jeffrey B Geske ◽  
Kyle W Klarich ◽  
Steve R Ommen ◽  
Hartzell V Schaff ◽  
Rick A Nishimura

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
V Jain ◽  
M.G Gupta ◽  
A.B Bansal ◽  
B.G Griffin ◽  
B.X Xu

Abstract Background Hypertrophic cardiomyopathy (HCM) is an inherited cardiovascular condition, associated with increased risk of premature adverse events. Once considered a disease of the young, it is increasingly being recognized in septuagenarians and octogenarians, with a few small-scale studies indicating that the risk of adverse cardiovascular outcomes may be lower in the older population. Purpose There are limited data regarding the outcomes of elderly patients with HCM. We therefore investigated a nationwide cohort in the United States to evaluate the pattern of disease presentation and outcomes of HCM patients, with a focus on the geriatric population. Methods The Nationwide Inpatient Sample (NIS) was queried to identify patients who were admitted for any cause with a concomitant diagnosis of HCM between 2011 and 2014 using ICD-9 (International Classification of Diseases-9th Edition-Clinical Modification) diagnosis code 425.1. All patients were further sub-categorized based on their age into those less than 65 years of age (representative of younger population), 66–75 years, 76–85 years and more than or equal to 86 years. We performed the Chi-squared tests for categorical variables and Mann–Whitney U tests for continuous variables. Multiple logistic regression was performed to assess the predictors of mortality. A two-tailed p-value of <0.05 was considered to be significant. Results We identified 120,805 patients who were admitted with a diagnosis of HCM, of whom 46.4% were in the <65 age group, 21.5% were in the 66–75 age group, 20.5% were in the 76–85 age group, and 11.5% were in the >86 age group. The proportion of patients with ventricular fibrillation was lower (1.8% vs 1.0% vs 0.5% vs 0.1%, p<0.01), whereas the proportion of patients undergoing permanent pacemaker placement was higher (1.2% vs 2.3% vs 3.7% vs 3.6%, p<0.01) in successive age groups. The proportion of people undergoing operative procedures including septal myectomy (SM) (5.4% vs 4.5% vs 1.8% vs 0.2%, p-intervention <0.01) and alcohol septal ablation (ASA) (3.2% vs 3.3% vs 1.9% vs 1.0%, p-intervention <0.01) were lower in the advanced age groups when compared to the younger age groups. Pacemaker implantation (odds ratio (OR): 0.32, 95% confidence intervals (CIs): 0.20–0.50, p<0.01) and implantable cardioverter defibrillator (ICD) placement (OR: 0.059, 95% CI: 0.024–0.144, p<0.01) were found to be associated with decreased odds of in-hospital mortality across all age groups. Conclusion In a large nationwide cohort of HCM patients in the United States, a significant proportion of patients were septuagenarians and octogenarians. Fewer elderly patients with HCM underwent septal myectomy and alcohol septal ablation, while elderly patients underwent more pacemaker implants. A combination of reduced ventricular conduction abnormalities coupled with increased pacemaker implantation may be contributing to increased longevity in older HCM patients. Odds-ratio for predictors of mortality Funding Acknowledgement Type of funding source: None


2016 ◽  
Vol 20 (3) ◽  
pp. 42
Author(s):  
R A Naydenov ◽  
E I Kretov ◽  
V I Baystrukov ◽  
O V Krestyaninov ◽  
R U Ibragimov ◽  
...  

<p><strong>Aim.</strong> The aim of this randomized study was to evaluate the safety and efficacy of septal myectomy (SM) and alcohol septal ablation (ASA) in patients with an obstructive form of hypertrophic cardiomyopathy.<br /><strong>Methods.</strong> The study included 76 patients eligible for ASA and Morrow myectomy. The patients were divided into two equal groups: one for ASA (n = 38), the other for SM.<br />The primary endpoint (combined) was to assess the safety, which included 30-day complications after surgery (mortality, bleeding, tamponade, stroke, development of VT / VF) and the frequency of pacemaker/ICD implantation.<br />Secondary endpoints focused on the evaluation of pressure gradient (efficiency), repeated operations, clinical and functional indicators, volume and mass of the ablation zone and dissected infarction. Control observation period was 12 months.<br /><strong>Results.</strong> By the end of control observations, it was found out that SM is a safer technique as compared to ASA, the complication rate was 13 % and 47 % respectively (log-rank test p = 0.0021; Cox: HR 11.4 95% CI [1.52 -11.1] p = 0.005). No significant differences in early (30 days) postoperative complications were found (log-rank test p = 0.24; Cox: HR 2.52, 95% CI [0.48-12.9] p = 0.27). Rhythm disturbances requiring pacemaker implantation / ICD (log-rank test p = 0.0029; Cox: HR 95% CI 4.92 [1.06-22.74] p = 0.042) were the most common complication. In both groups, there was a significant reduction of the LVOT gradient, p &lt;0.01. However, the residual gradient in the ASA group was significantly higher than that in the SM group, p &lt;0.01. Clinical data of both groups were comparable in the long term. A significant correlation was observed between the dissected infarction volume and the degree of reduction in the LVOT gradient of the SM group, p = 0.01. No significant dependency of the ablation zone volume on the degree of reduction in the LVOT gradient was observed, p = 0.7.<br /><strong>Conclusion.</strong> Septal myectomy is a safe treatment for hypertrophic cardiomyopathy as compared to ASA. Alcohol septal ablation and SM are comparable in the effectiveness of LVOT gradient reduction. There is a dependence of the excised myocardium volume and the degree of reduction in the LVOT gradient during long-term follow-up of patients who underwent Morrow SM.</p><p>Received 5 August 2016. Accepted 2 September 2016.</p><p><strong>Funding:</strong> The study had no sponsorship. <br /><strong>Conflict of interest:</strong> The authors declare no conflict of interest.</p>


Sign in / Sign up

Export Citation Format

Share Document